Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma

por Makhlin, Igor, Salinas, Ryan D, Zhang, Daniel, Jacob, Fadi, Ming, Gou-li, Song, Hongjun, Saxena, Deeksha, Dorsey, Jay F, Nasrallah, MacLean P, Morrissette, Jennifer JD, Binder, Zev A, O'Rourke, Donald M, Desai, Arati S, Brem, Steven, Bagley, Stephen J
Publicado 2019

Germline POT1 Variants Can Predispose to Myeloid and Lymphoid Neoplasms

por Lim, Tristan L., Lieberman, David B., Davis, Adam R., Loren, Alison W., Hausler, Ryan, Bigdeli, Ashkan, Li, Yimei, Powers, Jacquelyn, Raper, Anna, Carty, Shannon A., Nathanson, Katherine L., Bagg, Adam, Hexner, Elizabeth O., Maxwell, Kara N., Morrissette, Jennifer J.D., Babushok, Daria V.
Publicado 2021

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

por Echevarría‐Vargas, Ileabett M, Reyes‐Uribe, Patricia I, Guterres, Adam N, Yin, Xiangfan, Kossenkov, Andrew V, Liu, Qin, Zhang, Gao, Krepler, Clemens, Cheng, Chaoran, Wei, Zhi, Somasundaram, Rajasekharan, Karakousis, Giorgos, Xu, Wei, Morrissette, Jennifer JD, Lu, Yiling, Mills, Gordon B, Sullivan, Ryan J, Benchun, Miao, Frederick, Dennie T, Boland, Genevieve, Flaherty, Keith T, Weeraratna, Ashani T, Herlyn, Meenhard, Amaravadi, Ravi, Schuchter, Lynn M, Burd, Christin E, Aplin, Andrew E, Xu, Xiaowei, Villanueva, Jessie
Publicado 2018